Santen Pharmaceutical Co., Ltd. (FRA:SZD)
Germany · Delayed Price · Currency is EUR 9.20
-0.10 (-1.08%)
Last updated: Jan 28, 2026, 8:07 AM CET
Santen Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 31,003 | 35,853 | 26,703 | -14,983 | 27,189 | 6,645 |
Depreciation & Amortization | 18,094 | 17,948 | 18,178 | 17,249 | 17,055 | 16,768 |
Loss (Gain) From Sale of Assets | 1,302 | 1,302 | 7,779 | 34,560 | 232 | 40,664 |
Loss (Gain) on Equity Investments | 685 | 685 | 7,575 | 2,362 | 1,604 | 358 |
Other Operating Activities | -9,109 | -12,288 | -12,287 | -7,990 | -10,318 | -12,916 |
Change in Accounts Receivable | 10,010 | 18,512 | 18,384 | -6,443 | -1,965 | -7,514 |
Change in Inventory | -4,257 | -8,381 | -1,369 | -1,144 | 5,383 | -4,590 |
Change in Accounts Payable | -15,967 | -9,586 | -2,369 | 1,690 | 2,748 | 8,147 |
Change in Other Net Operating Assets | 14,432 | 16,883 | 10,055 | 11,846 | 4,115 | -8,754 |
Operating Cash Flow | 46,193 | 60,928 | 72,649 | 37,147 | 46,043 | 38,808 |
Operating Cash Flow Growth | -36.92% | -16.13% | 95.57% | -19.32% | 18.64% | -2.85% |
Capital Expenditures | -7,371 | -6,662 | -9,319 | -17,277 | -17,344 | -4,139 |
Cash Acquisitions | - | - | -207 | -3,470 | -2,969 | -29,183 |
Sale (Purchase) of Intangibles | -8,645 | -4,357 | -572 | -7,311 | -18,497 | -19,665 |
Investment in Securities | 3,051 | 3,152 | 3,826 | 1,560 | 2,803 | -314 |
Other Investing Activities | -352 | -356 | 127 | -279 | 838 | -54 |
Investing Cash Flow | -13,317 | -8,223 | -6,145 | -26,777 | -35,169 | -53,355 |
Short-Term Debt Issued | - | - | - | - | 10,460 | - |
Long-Term Debt Issued | - | - | - | 15,639 | 10,000 | 307 |
Total Debt Issued | - | - | - | 15,639 | 20,460 | 307 |
Short-Term Debt Repaid | - | - | - | -11,278 | - | - |
Long-Term Debt Repaid | - | -158 | -2,112 | - | - | -3,000 |
Total Debt Repaid | 1 | -158 | -2,112 | -11,278 | - | -3,000 |
Net Debt Issued (Repaid) | 1 | -158 | -2,112 | 4,361 | 20,460 | -2,693 |
Repurchase of Common Stock | -41,306 | -37,883 | -16,962 | -26,007 | - | - |
Common Dividends Paid | -12,422 | -12,111 | -11,881 | -12,607 | -11,994 | -11,188 |
Other Financing Activities | -3,315 | -3,155 | -3,076 | -2,967 | -2,909 | -2,804 |
Financing Cash Flow | -57,042 | -53,307 | -34,031 | -37,220 | 5,557 | -16,685 |
Foreign Exchange Rate Adjustments | 3,283 | -983 | 4,206 | 1,739 | 3,694 | 2,690 |
Miscellaneous Cash Flow Adjustments | 1 | - | - | - | 1 | - |
Net Cash Flow | -20,882 | -1,585 | 36,679 | -25,111 | 20,126 | -28,542 |
Free Cash Flow | 38,822 | 54,266 | 63,330 | 19,870 | 28,699 | 34,669 |
Free Cash Flow Growth | -41.06% | -14.31% | 218.72% | -30.76% | -17.22% | 1.60% |
Free Cash Flow Margin | 13.32% | 18.09% | 20.97% | 7.12% | 10.78% | 13.89% |
Free Cash Flow Per Share | 114.56 | 155.18 | 172.03 | 51.29 | 71.67 | 86.59 |
Cash Interest Paid | 1,163 | 1,093 | 830 | 465 | 240 | 159 |
Cash Income Tax Paid | 8,994 | 12,188 | 12,108 | 7,818 | 10,246 | 12,834 |
Levered Free Cash Flow | 19,944 | 40,191 | 57,849 | 10,007 | 6,630 | 23,856 |
Unlevered Free Cash Flow | 20,697 | 40,867 | 58,369 | 10,305 | 6,786 | 23,956 |
Change in Working Capital | 4,218 | 17,428 | 24,701 | 5,949 | 10,281 | -12,711 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.